Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations

ABSTRACT:

Background

Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (BRAF) mutations.

Methods

A retrospective study was conducted for patients with BRAF-mutant NSCLC who received treatment at Shanghai Pulmonary Hospital between 2014 and 2022. Primary end point was progression-free survival (PFS). Secondary end point was best response (RECIST, version 1.1).

Results

The study involved a total of 34 patients with 54 treatments recorded. The median PFS for the whole cohort was 5.8 months and the overall objective response rate (ORR) was 24%. Patients who were treated with ICI combined with chemother

SUBMITTER: Wang H 

PROVIDER: S-EPMC9989805 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature